Background/Aims: A substantial proportion of amyotrophic lateral sclerosis (ALS) patients develop cognitive impairments. Longitudinal investigations of cognition in ALS have shown mixed results. While some authors report that cognitive performance remains stable as the disease progresses, others have found evidence for deterioration in various domains. Our objective was to investigate cognitive performance in ALS longitudinally, using the example of executive functions. Methods: 93 ALS patients and 73 age-, sex- and education-matched healthy controls underwent up to four neuropsychological evaluations, separated by 3- to 6-month intervals. We examined whether performance declined longitudinally on seven tests assessing various sub-components of executive functioning. Furthermore, we assigned an executive-performance-based ‘cognitive status' to each participant for every evaluation, examining whether cognitive deterioration (if present) was modulated by their baseline cognitive status and whether cognitive status changed over time. Results: Regardless of their cognitive status at baseline, ALS patients showed no significant decline in the sub-components of executive functioning. Conclusion: Our findings imply that the executive deficits which develop in some ALS patients emerge before motor symptoms and remain stable after an initial decline. The discrepancy between this trajectory and the progressive decline in motor functions may result from a differential vulnerability of motor and non-motor prefrontal neurons to the pathomechanism of ALS.

Keywords:
Executive function, Amyotrophic lateral sclerosis, Cognition
1.
Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al: Amyotrophic lateral sclerosis. Lancet 2011;377:942-955.
2.
Phukan J, Pender NP, Hardiman O: Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol 2007;6:994-1003.
3.
Ringholz GM, Appel SH, Bradshaw M, Cooke NA, Mosnik DM, Schulz PE: Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology 2005;65:586-590.
4.
Gibbons ZC, Richardson A, Neary D, Snowden JS: Behaviour in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2008;9:67-74.
5.
Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al: Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006;314:130-133.
6.
Hamilton RL, Bowser R: Alzheimer's disease pathology in amyotrophic lateral sclerosis. Acta Neuropathol 2004;107:515-522.
7.
Lomen-Hoerth C, Murphy J, Langmore S, Kramer JH, Olney RK, Miller B: Are amyotrophic lateral sclerosis patients cognitively normal? Neurology 2003;60:1094-1097.
8.
Raaphorst J, de Visser M, Linssen WH, de Haan RJ, Schmand B: The cognitive profile of amyotrophic lateral sclerosis: a meta-analysis. Amyotroph Lateral Scler 2010;11:27-37.
9.
Rippon GA, Scarmeas N, Gordon PH, Murphy PL, Albert SM, Mitsumoto H, et al: An observational study of cognitive impairment in amyotrophic lateral sclerosis. Arch Neurol 2006;63:345-352.
10.
DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al: Expanded GGGGCCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011;72:245-256.
11.
Renton AE, Majounie E, Waite A, Simón-Sánchez J, Rollinson S, Gibbs JR, et al: A hexanucleotide repeat expansion in C90RF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011;72:257-268.
12.
Lillo P, Mioshi E, Burrell JR, Kiernan MC, Hodges JR, Hornberger M: Grey and white matter changes across the amyotrophic lateral sclerosis-frontotemporal dementia continuum. Plos One 2012;7:e43993.
13.
Tsermentseli S, Leigh PN, Goldstein LH: The anatomy of cognitive impairment in amyotrophic lateral sclerosis: more than frontal lobe dysfunction. Cortex 2011;48:166-182.
14.
Whitwell JL, Jack CR, Senjem ML, Josephs KA: Patterns of atrophy in pathologically confirmed FTLD with and without motor neuron degeneration. Neurology 2006;66:102-104.
15.
Gordon PH, Delgadillo D, Piquard A, Bruneteau G, Pradat P, Salachas F, et al: The range and clinical impact of cognitive impairment in French patients with ALS: a cross-sectional study of neuropsychological test performance. Amyotroph Lateral Scler 2011;12:372-378.
16.
Strong MJ, Yang W: The frontotemporal syndromes of ALS: clinicopathological correlates. J Mol Neurosci 2011;45:648-655.
17.
Taylor LJ, Brown RG, Tsermentseli S, Al-Chalabi A, Shaw CE, Ellis CM, et al: Is language impairment more common than executive dysfunction in amyotrophic lateral sclerosis? Amyotroph Lateral Scler 2013;84:494-498.
18.
Goldstein LH, Abrahams S: Changes in cognition and behaviour in amyotrophic lateral sclerosis: nature of impairment and implications for assessment. Lancet Neurol 2013;12:368-380.
19.
Strong MJ, Grace GM, Orange JB, Leeper HA, Menon RS, Aere C: A prospective study of cognitive impairment in ALS. Neurology 1999;53:1665-1670.
20.
Abrahams S, Leigh PN, Goldstein LH: Cognitive change in ALS: a prospective study. Neurology 2005;64:1222-1226.
21.
Gordon PH, Goetz RR, Rabkin JG, Dalton K, McElhiney M, Hays AP, et al: A prospective cohort study of neuropsychological test performance in ALS. Amyotroph Lateral Scler 2010;11:312-320.
22.
Moretti R, Torre P, Antonello RM, Carraro N, Cazzato G, Bava A: Complex cognitive disruption in motor neuron disease. Dement Geriatr Cogn Disord 2002;14:141-150.
23.
Kilani M, Micallef J, Soubrouillard C, Rey-Lardiller D, Dematteï C, Dib M, et al: A longitudinal study of the evolution of cognitive function and affective state in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2004;5:46-54.
24.
Schreiber H, Gaigalat T, Wiedemuth-Catrinescu U, Graf M, Uttner I, Muche R, Ludolph AC: Cognitive function in bulbar- and spinal-onset amyotrophic lateral sclerosis: a longitudinal study in 52 patients. J Neurol 2005;252:772-781.
25.
Elamin M, Bede P, Byrne S, Jordan N, Gallagher L, Wynne B, et al: Cognitive changes predict functional decline in ALS. Neurology 2013;80:1590-1597.
26.
Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases: El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:293-299.
27.
Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A: The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci 1999;169:13-21.
28.
Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al: The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695-699.
29.
Abrahams S, Leigh PN, Harvey A, Vythelingum GN, Grisé D, Goldstein LH: Verbal fluency and executive dysfunction in amyotrophic lateral sclerosis (ALS). Neuropsychologia 2000;38:734-747.
30.
Strong MJ, Grace GM, Freedman M, Lomen-Hoerth C, Woolley S, Goldstein LH, et al: Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2009;10:131-146.
31.
Phukan J, Elamin M, Bede P, Jordan N, Gallagher L, Byrne S, et al: The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry 2012;83:102-108.
32.
Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al: Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011;134:2456-2477.
33.
LoSasso G, Rapport LJ, Axelrod BN, Reeder KP: Intermanual and alternate-forms equivalence on the trail-making tests. J Clin Exp Neuropsychol 1998;20:107-110.
34.
Aggarwal A, Nicholson G: Detection of preclinical motor neurone loss in SOD1 mutation carriers using motor unit number estimation. J Neurol Neurosurg Psychiatry 2002;73:199-201.
35.
Carew JD, Nair G, Andersen PM, Wuu J, Gronka S, Hu X, Benatar M: Presymptomatic spinal cord neurometabolic findings in SOD1-positive people at risk for familial ALS. Neurology 2011;77:1370-1375.
36.
Ng M, Ho JT, Ho S, Lee R, Li G, Cheng T, et al: Abnormal diffusion tensor in nonsymptomatic familial amyotrophic lateral sclerosis with a causative superoxide dismutase 1 mutation. J Magn Reson Imaging 2008;27:8-13.
37.
Vucic S, Nicholson GA, Kiernan MC: Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain 2008;131:1540-1550.
38.
Benatar M, Wuu J: Presymptomatic studies in ALS: rationale, challenges, and approach. Neurology 2012;79:1732-1739.
39.
Reitan RM: Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills 1958;8:271-276.
40.
Wechsler D: Wechsler Memory Scale - Revised. San Antonio, The Psychological Corporation, 1987.
41.
Bäumler G (ed): Farb-Wort-Interferenztest (FWIT) nach J. R. Göttingen, Hogrefe, 1985.
42.
Aschenbrenner S, Tucha O, Lange KW: RWT - Regensburger Wortflüssigkeitstest (Handanweisung). Göttingen, Hogrefe, 2000.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.